TWI504391B - 誘發腫瘤缺氧於癌症治療上之用途 - Google Patents

誘發腫瘤缺氧於癌症治療上之用途 Download PDF

Info

Publication number
TWI504391B
TWI504391B TW098111832A TW98111832A TWI504391B TW I504391 B TWI504391 B TW I504391B TW 098111832 A TW098111832 A TW 098111832A TW 98111832 A TW98111832 A TW 98111832A TW I504391 B TWI504391 B TW I504391B
Authority
TW
Taiwan
Prior art keywords
tumor
stilbene
agent
tirapazamine
hypoxic
Prior art date
Application number
TW098111832A
Other languages
English (en)
Chinese (zh)
Other versions
TW201002312A (en
Inventor
Ruey-Min Lee
Peck-Sun Lin
Original Assignee
Univ Virginia Commonwealth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Virginia Commonwealth filed Critical Univ Virginia Commonwealth
Publication of TW201002312A publication Critical patent/TW201002312A/zh
Application granted granted Critical
Publication of TWI504391B publication Critical patent/TWI504391B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Botany (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TW098111832A 2008-04-10 2009-04-09 誘發腫瘤缺氧於癌症治療上之用途 TWI504391B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4396408P 2008-04-10 2008-04-10

Publications (2)

Publication Number Publication Date
TW201002312A TW201002312A (en) 2010-01-16
TWI504391B true TWI504391B (zh) 2015-10-21

Family

ID=41162569

Family Applications (1)

Application Number Title Priority Date Filing Date
TW098111832A TWI504391B (zh) 2008-04-10 2009-04-09 誘發腫瘤缺氧於癌症治療上之用途

Country Status (6)

Country Link
US (4) US8591921B2 (enExample)
JP (2) JP5731372B2 (enExample)
KR (1) KR101925436B1 (enExample)
CN (2) CN104043125B (enExample)
TW (1) TWI504391B (enExample)
WO (1) WO2009126705A2 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2592103Y2 (ja) 1992-07-23 1999-03-17 東海旅客鉄道株式会社 ケーブルトラフ
CA2613312C (en) 2005-06-29 2014-10-14 Threshold Pharmaceuticals, Inc. Phosphoramidate alkylator prodrugs
WO2009126705A2 (en) 2008-04-10 2009-10-15 Virginia Commonwealth University Induction of tumor hypoxia for cancer therapy
EP3311835B1 (en) * 2010-07-12 2021-03-24 Threshold Pharmaceuticals Inc. Administration of hypoxia activated prodrugs and antiangiogenic agents for the treatment of cancer
EP2407161A1 (en) * 2010-07-13 2012-01-18 Sanofi An antitumoral combination comprising ombrabulin and bevacizumab
WO2012145684A1 (en) 2011-04-22 2012-10-26 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Transient hypoxia inducers and their use
US9254299B2 (en) 2011-12-22 2016-02-09 Threshold Pharmaceuticals, Inc. Administration of hypoxia activated prodrugs in combination with Chk1 inhibitors for treating cancer
CN102512692B (zh) * 2012-01-16 2014-07-16 北京大学 肿瘤靶向栓塞治疗组合物及其制备方法
AU2013204313C1 (en) 2012-06-01 2016-04-07 Bionomics Limited Combination Therapy
WO2015069489A1 (en) 2013-11-06 2015-05-14 Merck Patent Gmbh Predictive biomarker for hypoxia-activated prodrug therapy
CA2930001A1 (en) * 2013-11-11 2015-05-14 University Hospitals Cleveland Medical Center Targeted treatment of anerobic cancer
US9586056B2 (en) * 2014-07-03 2017-03-07 Haniva Llc Combination therapy for treating cancer and method for treating cancer using a combination therapy
ES2822557T3 (es) * 2014-08-08 2021-05-04 Poseida Therapeutics Inc Composiciones y su uso para inducir la embolización microvascular de tumores mediada por nanopartículas
EP3250215B1 (en) 2015-01-29 2025-04-09 Oxyrase, Inc. Methods for inhibiting tumor growth
US20180127748A1 (en) * 2015-05-15 2018-05-10 The General Hospital Corporation Methods relating to the prevention and treatment of drug resistance
US10456452B2 (en) 2015-07-02 2019-10-29 Poseida Therapeutics, Inc. Compositions and methods for improved encapsulation of functional proteins in polymeric vesicles
IL309273A (en) * 2015-10-21 2024-02-01 Teclison Ltd Compositions and methods for immune-mediated cancer therapy
ES2865481T3 (es) 2016-04-29 2021-10-15 Poseida Therapeutics Inc Micelas basadas en poli(histidina) para la complejación y el aporte de proteínas y ácidos nucleicos
WO2017197342A1 (en) * 2016-05-13 2017-11-16 Teclison Limited Methods for treating liver tissue
CN107007571B (zh) * 2017-02-24 2020-08-21 福州市传染病医院 肿瘤微酸性敏感的铜-药物共配位自组装纳米粒及应用
CN110051848A (zh) * 2019-05-06 2019-07-26 中国科学院长春应用化学研究所 药物组合、应用以及抗肿瘤的药物
CN110585214A (zh) * 2019-09-25 2019-12-20 湖北大学 一种促进治疗肿瘤效果的纳米粒子及其合成方法
CN110713596B (zh) * 2019-11-08 2022-04-29 西北师范大学 肿瘤无导管栓塞用pH-还原双响应高分子栓塞剂及其合成
CN112961082B (zh) * 2021-02-22 2022-09-06 沈阳药科大学 一种血管阻断剂与双载药仿生脂质体联用的给药系统
JP7730130B2 (ja) * 2021-03-02 2025-08-27 ドリームメディカルパートナーズ株式会社 塞栓材及びその製造方法
WO2023049207A1 (en) * 2021-09-22 2023-03-30 The University Of Texas System Quantitative magnetic resonance imaging and tumor forecasting
CN114344482B (zh) * 2022-01-14 2023-05-12 重庆医科大学附属第二医院 一种基于金属有机骨架的多功能纳米粒及其制备方法与应用
WO2024006901A1 (en) * 2022-06-29 2024-01-04 Diffusion Pharmaceuticals Llc Uses of bipolar trans carotenoids in the treatment of cancer

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3980779A (en) 1972-02-01 1976-09-14 Bayer Aktiengesellschaft 3-Amino-1,2,4-benzotriazine-1,4-di-N-oxide compositions and method of using same
US5175287A (en) 1986-09-25 1992-12-29 S R I International Process for preparing 1,2,4-benzotriazine oxides
US5616584A (en) 1986-09-25 1997-04-01 Sri International 1,2,4-benzotriazine oxides as radiosensitizers and selective cytotoxic agents
ATE130517T1 (de) * 1990-08-08 1995-12-15 Takeda Chemical Industries Ltd Intravaskulär embolisierendes mittel mit gehalt an einem die angiogenesis hemmenden stoff.
PT1155689E (pt) 1993-07-19 2007-01-31 Angiotech Pharm Inc Composições anti-angiogenicas e metodos de utilização
US5484612A (en) 1993-09-22 1996-01-16 The Board Of Trustees Of The Leland Stanford Junior University Method of treating a mammal having a solid tumor susceptible to treatment with cisplatin
GB9404400D0 (en) 1994-03-07 1994-04-20 Wood Pauline J Potentiation of bioreductive agents
DE69835824T2 (de) 1997-03-07 2007-03-29 Sanofi-Aventis U.S. Llc Antitumorkombination aus 3-amino-1,2,4-benzotriazine 1,4-dioxid/paclitaxel/platin
DE10012120A1 (de) 2000-03-13 2001-09-27 Ktb Tumorforschungs Gmbh Therapeutische und diagnostische Ligandensysteme mit Transportmolekülbindenden Eigenschaften und diese enthaltende Arzneimittel
JP2005504070A (ja) * 2001-09-13 2005-02-10 コリア・インスティテュート・オブ・サイエンス・アンド・テクノロジー 化学塞栓用油性パクリタキセル組成物及び処方物並びにその製造方法
JP2006515885A (ja) * 2003-01-17 2006-06-08 スレッシュオールド ファーマシューティカルズ， インコーポレイテッド 癌の処置のための併用療法
JP2006519209A (ja) * 2003-02-26 2006-08-24 ファルマシア・イタリア・ソシエタ・ペル・アツィオーニ ネモルビシン（ｎｅｍｏｒｕｂｉｃｉｎ）の肝臓内投与により肝臓癌を治療するための方法
ITRM20030355A1 (it) 2003-07-18 2005-01-19 Sigma Tau Ind Farmaceuti Composti ad attivita' citotossica derivati della combretastatina.
US20080108664A1 (en) 2005-12-23 2008-05-08 Liu Belle B Solid-state form of AMG 706 and pharmaceutical compositions thereof
WO2009126705A2 (en) 2008-04-10 2009-10-15 Virginia Commonwealth University Induction of tumor hypoxia for cancer therapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Int J Radiat Oncol Biol Phys. Volume 29, Issue 2, 15May 1994 Pages373-377 Int J Radiat Oncol Biol Phys. 2000 Jun 1;47(3):799-807 Cancer Res 2006; 66:1664-16746 Int J Radiat Biol. 1995 Feb;67(2):211-216 Biochemistry 1999, 38, 14248-14255 2006年11月9日，「針對缺氧癌細胞的新療法：Tirapazamine」 *

Also Published As

Publication number Publication date
US20140065139A1 (en) 2014-03-06
US10426779B2 (en) 2019-10-01
KR20110050583A (ko) 2011-05-16
KR101925436B1 (ko) 2018-12-05
JP2015110602A (ja) 2015-06-18
WO2009126705A3 (en) 2010-02-18
US20120087913A1 (en) 2012-04-12
CN102026634B (zh) 2014-01-22
US8591921B2 (en) 2013-11-26
JP5944018B2 (ja) 2016-07-05
WO2009126705A8 (en) 2011-04-14
TW201002312A (en) 2010-01-16
US20170224693A1 (en) 2017-08-10
CN104043125B (zh) 2018-01-12
HK1202057A1 (en) 2015-09-18
WO2009126705A2 (en) 2009-10-15
JP2011516565A (ja) 2011-05-26
CN102026634A (zh) 2011-04-20
US9649316B2 (en) 2017-05-16
JP5731372B2 (ja) 2015-06-10
US10159676B2 (en) 2018-12-25
CN104043125A (zh) 2014-09-17
US20180050039A1 (en) 2018-02-22

Similar Documents

Publication Publication Date Title
TWI504391B (zh) 誘發腫瘤缺氧於癌症治療上之用途
Miller et al. Poly (ethylene glycol)–paclitaxel–alendronate self-assembled micelles for the targeted treatment of breast cancer bone metastases
CN105338977A (zh) 艾日布林和乐伐替尼作为治疗癌症的联合疗法的用途
US11129830B2 (en) PAC-1 combination therapy
You et al. Chemoradiation therapy using cyclopamine-loaded liquid–lipid nanoparticles and lutetium-177-labeled core-crosslinked polymeric micelles
US10278954B2 (en) Method of treating a CNS disorder using a water-soluble histone deacetylase inhibitor
US20120214758A1 (en) Tyrosine kinase receptor antagonists and methods of treatment for pancreatic cancer
Clémenson et al. The vascular disrupting agent ombrabulin (AVE8062) enhances the efficacy of standard therapies in head and neck squamous cell carcinoma xenograft models
CN110062633A (zh) 酪氨酸衍生物以及包含所述酪氨酸衍生物的组合物
Garona et al. Addition of vasopressin synthetic analogue [V4Q5] dDAVP to standard chemotherapy enhances tumour growth inhibition and impairs metastatic spread in aggressive breast tumour models
PT2349268E (pt) N,n¿-dióxidos de 3,3¿,4,4¿-tetrahidroxi-2,2¿-bipiridina para o tratamento de carcinoma de células renais
AU2013208649B2 (en) Combination therapy for the treatment of cancer
Durrant et al. cis-3, 4′, 5-Trimethoxy-3′-aminostilbene disrupts tumor vascular perfusion without damaging normal organ perfusion
Bergström et al. Effects of amifostine on cisplatin induced DNA adduct formation and toxicity in malignant glioma and normal tissues in rat
Mander et al. Advancing drug therapy for brain tumours: A current review of the pro-inflammatory peptide substance P and its antagonists as anti-cancer agents
HK1202057B (en) Induction of tumor hypoxia for cancer therapy
Horsman et al. The oxygen effect and therapeutic approaches to tumour hypoxia
KR20090021211A (ko) 약물 투여 방법
Liu et al. A rat toxicological study of intra-arterial injection of Tirapazamine, a hypoxia-activating Cancer therapeutic agent, followed by hepatic artery ligation
Skitzki et al. A Phase 1 Study of Intra-Arterial CBL0137 in Extremity Melanomas and Sarcomas
WO1998058634A2 (en) Intratumoral administration of triphenylethylenes for the treatment of cancer
JP2011079788A (ja) 膵癌に対する選択的膵動脈制癌剤注入療法と全身化学療法との併用療法、およびそれに使用する膵癌治療薬
US20050095196A1 (en) Method for using potassium channel agonists for delivering a medicant to an abnormal brain region and/or a malignant tumor
JP2004521929A (ja) イソクマリン誘導体を使用する腫瘍の放射線増感および／または化学相乗作用
JP2015091766A (ja) 癌治療支援システム